Eric Easom - 20 Feb 2026 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
Chief Executive Officer, Director
Signature
/s/ Lucy Day, Attorney-in-Fact for Eric Easom
Issuer symbol
ANTX
Transactions as of
20 Feb 2026
Net transactions value
$0
Form type
4
Filing time
23 Feb 2026, 16:36:44 UTC
Previous filing
03 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Easom Eric Chief Executive Officer, Director C/O AN2 THERAPEUTICS, INC., 1300 EL CAMINO REAL, SUITE 100, MENLO PARK /s/ Lucy Day, Attorney-in-Fact for Eric Easom 23 Feb 2026 0001914503

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANTX Common Stock Award $0 +112,250 +44% $0.000000 368,630 20 Feb 2026 Direct F1, F2
holding ANTX Common Stock 1,065,766 20 Feb 2026 See Footnote F3
holding ANTX Common Stock 97,058 20 Feb 2026 See Footnote F4
holding ANTX Common Stock 97,058 20 Feb 2026 See Footnote F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANTX Stock Option (right to buy) Award $0 +224,500 $0.000000 224,500 20 Feb 2026 Common Stock 224,500 $1.04 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.
F2 Includes a balance of (i) 145,250 RSUs which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2025 and (ii) 99,000 RSUs which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2024, in each case subject to the Reporting Person's continuous service through each applicable vesting date.
F3 Consists of shares of Common Stock held by the Easom Living Trust dated August 21, 2019.
F4 Consists of shares of Common Stock held by the C. Easom Irrevocable Trust dated October 8, 2021.
F5 Consists of shares of Common Stock held by the Jude Easom Irrevocable Trust dated October 8, 2021.
F6 The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.